van Rijckevorsel Patil AA, Andrews RV, Johnson M, et al. 2004. Is epilepsy surgery on both hemispheres effective? Stereotact Funct Neurosurg, 82:214–21. Patwardhan RV, Stong B, Bebin EM, et al. 2000. Efficacy of vagal nerve stimulation in children with medically refractory epilepsy. Neurosurgery, 47:1353–1357; discussion 1357–8. Parker AP, Polkey CE, Binnie CD, et al. 1999. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics, 103:778–82. Pechadre JC, Sauvezie B, Osier C, et al. 1977. Traitement des encéphalopathies épileptiques de l’enfant par les gammaglobulines. Rev EEG Neurophysiol Clin, 7:443–7. Peled N, Shorer Z, Peled E, et al. 2001. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia, 42:1208–10. Pellock JM, Faught E, Leppik IE, et al. 2006. Felbamate: consensus of current clinical experience. Epilepsy Res, 71:89–101. Pendl G, Eder HG, Schroettner O, et al. 1999. Corpus callosotomy with radiosurgery. Neurosurgery, 45:303–7. Perucca E, Gram L, Avanzini G, et al. 1998. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia, 39:5–17. Perucca E, French J, Bialer M. 2007. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol, 6:793–804. Perucca E, Cloyd J, Critchley D, et al. 2008. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy: Epilepsia, 49:1123–41. Peters DH, Sorkin EM. 1993. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs, 45:760–87. Pieribone VA, Tsai J, Soufflet C, et al. 2007. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia, 48:1870–4. Pinder RM, Brogden RN, Speight TM, et al. 1976. Clonazepam: a review of its pharmacological properties and therapeutic efﬁcacy in epilepsy. Drugs, 12:321–61. Purves SJ, Wada JA, Woodhurst WB, et al. 1988. Results of anterior corpus callosum section in 24 patients with medically intractable seizures. Neurology, 38:1194–201. Quarato PP, Gennaro GD, Manfredi M, et al. 2002. Atypical Lennox- Gastaut syndrome successfully treated with removal of a parietal dysembryoplastic tumour. Seizure, 11:325–9. Quilichini PP, Chiron C, Ben-Ari Y, et al. 2006. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA- receptor channels. Epilepsia, 47:704–16. Rathore C, Abraham M, Rao RM, et al. 2007. Outcome after corpus callosotomy in children with injurious drop attacks and severe mental retardation. Brain Dev, 29:577–85. Reutens DC, Bye AM, Hopkins IJ, et al. 1993. Corpus callosotomy for intractable epilepsy: seizure outcome and prognostic factors. Epilepsia, 34:904–9. Ritter FJ, Glauser TA, Sachdeo RC, et al. 1998. Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia, 39(S2):2–3. Roecklein BA, Sacks HJ, Mortko H, et al. 2007. New Antiepileptic Drugs: Discovery, Development, and Update. Part 2: Progress in current AED development: The drugs. Fluorofelbamate. Neuro Therapeutics, 4:97–101. Rogawski MA. 2006. Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline. Epilepsy Res, 69:273–94. Roger J, Dravet C, Bureau M. 1989. The Lennox-Gastaut syndrome. Cleve Clin J Med, 56(S2):S172–80. Rougier A, Claverie B, Pedespan JM, et al. 1997. Callosotomy for intractable epilepsy: overall outcome. J Neurosurg Sci, 41:51–7. Rychlicki F, Zamponi N, Trignani R, et al. 2006. Vagus nerve stimulation: clinical experience in drug-resistant pediatric epileptic patients. Seizure, 15(7):483–90 Sachdeo R, Kugler S, Wenger E, et al.1996. Topiramate in Lennox-Gastaut syndrome. Epilepsia, 37(S4):118(Abstract). 1018 Sachdeo RC, Glauser TA, Ritter R, et al. 1999. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology, 52:1882–7. Sakurai K, Tanaka N, Kamada K, et al. 2006. Magnetoencephalographic studies of focal epileptic activity in three patients with epilepsy suggestive of Lennox-Gastaut syndrome. Epileptic Disord, 9:158–63. Santos CC, Brotherton T. 2005. Use of zonisamide in pediatric patients. Pediatr Neurol, 33:12–4. Sazgar M, Bourgeois BF. 2005. Aggravation of epilepsy by antiepileptic drugs. Pediatric Neurology, 33:227–34. Schmidt D, Bourgeois B. 2000. A risk-beneﬁt assessment of therapies for Lennox-Gastaut syndrome. Drug Saf, 22:467–77. Schlumberger E, Chavez F, Palacios L, et al. 1994. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia, 35:359–67. Scott RC, Besag FM, Neville BG. 1999. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet, 353:623–6. Siegel H, Kelley K, Stertz B, et al. 1999. The efﬁcacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsy Res, 34:91–7. Sinclair DB. 2003. Prednisone therapy in pediatric epilepsy. Pediatr Neurol, 28:194–8. Sorel L, Dusaucy-Bauloye A. 1958. A propos de 21 cas d’hypsarrhythmia de Gibbs: Son traitement spectaculaire par l’ACTH. Acta Neurol Belg, 58:130–41. Spencer SS, Schramm J, Wyler A, et al. 2002. Multiple subpial transection for intractable partial epilepsy: an international meta-analysis. Epilepsia, 43:141–5. Stêpieñ K, Tomaszewski M, Czuczwar SJ. 2005. Proﬁle of anticonvulsant activity and neuroprotective effects of novel and potential antiepileptic drugs – an update. Pharmacological Reports, 57:719–33. Sterio M, Gebauer E, Felle D, et al. 1992. Malignant epilepsy in children: therapy with high doses of intravenous immunoglobulin. Med Pregl, 45:220–4. Swink TD, Vining EP, Freeman JM. 1997. The ketogenic diet: 1997. Adv Pediatr, 44:297–329. Tanabe T, Awaya Y, Matsuishi T, et al. 2008. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome) – A nationwide questionnaire survey in Japan. Brain Dev, Available online 17 April 2008. Tartara A, Sartori I, Manni R, et al. 1996. Efﬁcacy and safety of topiramate in refractory epilepsy: a long-term prospective trial. Ital J Neurol Sci, 17:429–32. Tassinari CA, Dravet C, Roger J, et al. 1972. Tonic status epilepticus precipitated by intravenous benzodiazepines in ﬁve patients with Lennox-Gastaut syndrome. Epilepsia, 13:421–35. Technology Evaluation Center. 2003. MEG ans MSI: Presurgical localization of epileptic lesions and presurgical function mapping. Assessment Program, 18:1–27. The Group for the evaluation of cinromide in the Lennox-Gastaut syndrome. 1989. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia, 30:422–9. Timmings PL, Richens A. 1992. Lamotrigine as add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol, 32:305–7. Tran A, Vauzelle-Kervroëdan F, Rey E, et al. 1996. Effect of stiripentol on CBZ plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol, 50:497–500. Trevathan E, Murphy CC, Yeargin-Allsopp M. 1997. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia, 38(12):1283–8. Trimble MR. 2002. On the use of tranquillisers in epilepsy. Epilepsia, 43(S2):25–7. Uvebrant P, Bauzienè R. 1994. Intractable epilepsy in children. The efﬁcacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics, 25:284–9. Neuropsychiatric Disease and Treatment 2008:4(6)